UNITAID: Tuberculosis diagnostics technology and market landscape – 3rd edition

The report highlights current and emerging technologies to diagnose tuberculosis from over 80 manufacturers and developers.

Read More →

Two new activist guides on delamanid and linezolid

Both guides describe what activists—including people with TB, researchers, and doctors who treat TB—can do to help ensure access, fair pricing, and further research.

Read More →

Child TB training toolkit launched by WHO and The Union

The training focuses on building the capacity of health care workers at the primary and secondary level to address and manage TB in children.

Read More →

The Union announces complete programme of the 45th World Conference on Lung Health

WHO to release annual Global Tuberculosis Report in advance of the event; Looming co-epidemic of TB and diabetes to be a major focus of the conference; 1st international parliamentarian TB summit to precede the conference.

Read More →

Obama Administration takes actions to combat antibiotic-resistant bacteria

President Obama signed an Executive Order directing key Federal departments and agencies to take action to combat the rise of antibiotic-resistant bacteria.

Read More →

Janssen's response to open letter calling on the company to reduce the price of bedaquiline

Several organizations and individuals working on TB appealed to Janssen to lower bedaquiline's price for all non-high-income countries.

Read More →

A new report analyses gaps in TB/HIV services in Ukraine

TB is both the most significant AIDS-related disease and the leading cause of death in PLHIV in Ukraine. The dual epidemics of TB and HIV continue to have significant impacts in the country, and pose multiple challenges for effective management and treatment of people living with HIV and TB.

Read More →

Open letter to Janssen: Reducing the price of bedaquiline

Several organizations and individuals working on TB appeal to Janssen to lower bedaquiline's price for all non-high-income countries.

Read More →

Attempt to shorten standard tuberculosis treatment fails in REMoxTB trial

Two 4-month treatment regimens containing moxifloxacin are less effective than the standard 6-month regimen for drug-sensitive tuberculosis.

Read More →

Global epidemic of diabetes threatens to jeopardise further progress in tuberculosis control

A Series of three papers in The Lancet Diabetes & Endocrinology examines the intersection between TB and diabetes from several angles, and outlines strategies that will be key to managing and ultimately reducing this dual disease burden.

Read More →

Page 1 of 44 · Total posts: 10

Older posts →

Login or register to be notified of new posts.

TAC logo TAG logo i-base logo EATG logo SADF logo CMT logo

TB Online is supported by the Treatment Action Campaign, Community Media Trust, South Africa Development Fund, Treatment Action Group, European AIDS Treatment Group and HIV i-Base.

The original material on this site is licensed under a Creative Commons Attribution 3.0 Unported License. Articles and images provided by 3rd-parties are subject to their licenses, though we strive to use free and open source materials wherever possible.
Creative Commons Licence badge